ERR

T

Q

Q

hw

Q

dt

Q

ptp

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:371

xam 2: Allopurinol to Prevent Pancreatitis After ERCP: Aandomized Placebo-Controlled Trial

omagnuolo, et al, Authors

est ID No.: 0055 Contact hours: 1.0 Expiration Date: April 30, 2009

uestion 1:

b

The most common complication of ERCP is?

d

uestion 2:

b

d

uestion 3:

b

d

uestion 4:

ancreatitis except:

b

d

a) Perforation) Pancreatitis

c) Bleeding

) Death

An attractive property of allopuriol, a xanthine oxidase in-ibitor for the prevention of post-ERCP pancreatitis, includeshich one of the following:

a) Antioxidant and anti-apoptotic properties in humans) High oral bioavailability and long half life

c) Inexpensive) B and c

e) All of the above

To date, which intervention has been shown to effectivelyecrease the rate of post-ERCP pancreatitis in high risk pa-ients?

a) NSAIDS) Protease inhibitors such as gabexate

c) Octreotide

) Pancreatic stents

In this trial of allopurinol versus placebo in the prevention ofost-ERCP pancreatitis, the logistic regression analysis showedhat all of the following are significant predictors of post-ERCP

a) Previous post-ERCP pancreatitis) Pancreatic injection

c) Pancreatic endotherpay

) Pancreatic stent placement